I've appreciated the discussion regarding Humanigen's latest patent, which includes a second drug consisting of an anti-viral, a vaccine, and polyclonal antibodies.
I particularly want to note dlog's point that it makes no sense to take a vaccine, if you already have covid.
So I have done some additional research, and I have concluded that our second drug compound, with the vaccine component, may not be intended for patients with covid after all. Rather, I think this second drug may be intended as a postexposure prophylaxis (PEP), especially for vulnerable patients domiciled with infected members of the household.
And perhaps surprisingly, studies have shown that there may be a favorable cost benefit.
"April 22, 2022 Estimated Health Outcomes and Costs of COVID-19 Prophylaxis With Monoclonal Antibodies Among Unvaccinated Household Contacts in the US
...Conclusions and Relevance
In this modeling study of a simulated US population, a mAb PEP for COVID-19 program was estimated to improve health outcomes and reduce costs. In the setting of a susceptible variant of SARS-CoV-2, health system and public health actors would have an opportunity to improve health and reduce net payer costs through COVID-19 PEP with mAbs..."
“Promising advances in efforts to isolate and develop mAbs with activity against a broad range of sarbecoviruses could lessen the risk of loss of activity with future SARS-CoV-2 genotypes/variants,” the study authors noted.
One variant-agnostic therapy currently under development is Humanigen’s monoclonal antibody lenzilumab, which showed promise for treating hyperinflammatory response to SARS-CoV-2 infection in recently published phase 3 trials."
News 
Market Data 
Discover 
